We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Reata Pharmaceuticals Inc
10 own
10 watching
Current Price
$92.31
$-0.23
(-0.25%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
3,385.51M
52-Week High
106.69
52-Week Low
18.47
Average Volume
0.38M
Dividend Yield
--
P/E Ratio
--
Market Capitalization3,385.51M52-Week High106.6952-Week Low18.47Average Volume0.38MDividend Yield--P/E Ratio--What does the Reata Pharmaceuticals Inc do?
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Read More
How much money does Reata Pharmaceuticals Inc make?
News & Events about Reata Pharmaceuticals Inc.
Benzinga
1month ago
read more...
Business Wire
1month ago
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Reata Pharmaceuticals, Inc. (NasdaqGM: RETA). In December 2021, the U.S. Food and Drug Administration (FDA...
PR Newswire
2 months ago
REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK &...
Ticker Report
2 months ago
Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA Get Rating) have received a consensus rating of Moderate Buy from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold ...
Frequently Asked Questions
Frequently Asked Questions
What is Reata Pharmaceuticals Inc share price today?
Can Indians buy Reata Pharmaceuticals Inc shares?
How can I buy Reata Pharmaceuticals Inc shares from India?
Can Fractional shares of Reata Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Reata Pharmaceuticals Inc stocks?
What is today’s traded volume of Reata Pharmaceuticals Inc?
What is today’s market capitalisation of Reata Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Reata Pharmaceuticals Inc?
What percentage is Reata Pharmaceuticals Inc down from its 52-Week High?
What percentage is Reata Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$92.31
$-0.23
(-0.25%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.